LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

Search

TG Therapeutics Inc

Chiusa

SettoreSettore sanitario

35.47 1.49

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.6

Massimo

35.59

Metriche Chiave

By Trading Economics

Entrata

-18M

5.1M

Vendite

13M

121M

P/E

Media del settore

139.96

56.602

EPS

0.03

Margine di Profitto

4.187

Dipendenti

338

EBITDA

-23M

8.6M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+24.36% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

784M

5.6B

Apertura precedente

33.98

Chiusura precedente

35.47

Notizie sul Sentiment di mercato

By Acuity

60%

40%

364 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

TG Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 ago 2024, 20:01 UTC

Utili

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Confronto tra pari

Modifica del prezzo

TG Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

24.36% in crescita

Previsioni per 12 mesi

Media 43.5 USD  24.36%

Alto 55 USD

Basso 11 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TG Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

6

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 34.86Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

364 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.